Bit delayed in posting this one, but here goes...
In what feels like a corporate soap opera, Pfizer's latest episode with activist investor Starboard Value has taken an eyebrow-raising twist. Just days before a crucial meeting with CEO Albert Bourla, two former top executives performed such a dramatic about-face that it would make a gymnast jealous.
The Curious Case of the Backtracking Executives
Former CEO Ian Read and ex-CFO Frank D'Amelio were apparently all ears when it came to Starboard's concerns about Pfizer's direction. They even went as far as expressing their own worries about the company's trajectory and offered to help. But then, in a move that screams "nothing to see here," they suddenly issued a late-night statement washing their hands of the whole affair.
The timing? Suspicious. The wording? Straight out of the corporate PR playbook: "We are fully supportive of Pfizer Chairman & CEO Albert Bourla, senior management and the board." Nothing says genuine like a midnight declaration of undying support, right?
But Wait, There's More...
Starboard Value isn't buying this convenient change of heart. In fact, they're suggesting something far more troubling: alleged strong-arm tactics from within Pfizer. According to Starboard, these former executives faced threats of legal action and potential clawbacks of compensation unless they publicly backed Bourla. Nothing like a little corporate arm-twisting to ensure loyalty!
The Numbers Don't Lie
While this drama unfolds, let's look at the cold, hard facts:
Pfizer's stock is hovering around $30 - a far cry from its pandemic glory days of nearly $60
The company's revenue plummeted 41% in 2023
Management went on a $70 billion shopping spree, including a whopping $43 billion for Seagen
All this while the company struggles to find its post-pandemic footing. Is it any wonder shareholders might be interested in what Starboard has to say?
The Plot Thickens
The upcoming October 16th meeting between Starboard and Bourla promises to be interesting, to say the least. With Starboard's $1 billion stake in the company, they're not exactly showing up with empty pockets. Some shareholders are apparently even whispering about replacing Bourla altogether.
One thing's certain: for a company that prides itself on developing medicines, Pfizer's current situation looks like it might need some corporate therapy of its own.
Comments